Patent US5204370A successfully refreshed from Google Patents.
US5204370A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
Assignee: Eli Lilly and Co
•
Filing: 1990-11-05
•
Granted: 1993-04-20
•
Expires: 2010-11-05
Abstract
Abstract The present invention provides novel substituted anthraquinones having the formula <IMAGE> wherein R1 and R2 are independently H, C1-C10 alkyl, aryl, arylalkyl, alkylaryl; n and m are independently 1, 2, or 3; A is Halogen, OH, alkoxy, OCO(NR3R4), S-C(NH2)=NR5, or when m=1, comprises an oxirane ring with the adjacent oxygen atom; R3, R4, and R5 are independently H, alkyl, or aryl; X is H, OH, NR6R7, Cl, Br, I, F, alkyl, aryl, alkoxy, aryloxy, COOR8, or CONR9R10; and R6, R7, R8, R9, and R10 are independently H, lower alkyl, or aryl useful for inhibiting protein kinase C and treating conditions related to, or affected by inhibition of protein kinase C, particularly cancer tumors, inflammatory disease, reperfusion injury, and cardiac dysfunctions related to reperfusion injury.
Inventors
- 👤 Jack B. Jiang
- 👤 Mary G. Johnson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 16:12
CPC Classifications
C; C07; C07C; C07C225/00; C07C225/24; C07C225/26; C07C225/32; C07C225/34; C07C225/36; C07D; C07D303/00; C07D303/02; C07D303/36
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
124 words
A substituted anthraquinone having the formula ##STR4## wherein R 1 and R 2 are independently H, C 1 -C 10 alkyl, aryl, arylalkyl, alkylaryl; n and m are independently 1, 2, or 3; A is Halogen, OH, alkoxy, OCO(NR 3 R 4 ), S--C(NH 2 )═NR 5 , or when m=1, comprises an oxirane ring with the adjacent oxygen atom; R 3 , R 4 , and R 5 are independently H, alkyl, or aryl; X is H, OH, NR 6 R 7 , Cl, Br, I, F, alkyl, aryl, alkoxy, aryloxy, COOR 8 , or CONR 9 R 10 ; and R 6 , R 7 , R 8 , R 9 , and R 10 are independently H, lower alkyl, or aryl.
Claim 2
Dependent Claim
124 words
A substituted anthraquinone having the formula ##STR4## wherein R 1 and R 2 are independently H, C 1 -C 10 alkyl, aryl, arylalkyl, alkylaryl; n and m are independently 1, 2, or 3; A is Halogen, OH, alkoxy, OCO(NR 3 R 4 ), S--C(NH 2 )═NR 5 , or when m=1, comprises an oxirane ring with the adjacent oxygen atom; R 3 , R 4 , and R 5 are independently H, alkyl, or aryl; X is H, OH, NR 6 R 7 , Cl, Br, I, F, alkyl, aryl, alkoxy, aryloxy, COOR 8 , or CONR 9 R 10 ; and R 6 , R 7 , R 8 , R 9 , and R 10 are independently H, lower alkyl, or aryl.
Claim 3
Dependent Claim
76 words
The substituted anthraquinone of claim 1 wherein R 1 and R 2 independently are H or lower alkyl; n and m are independently 1 or 2; A is halogen, OCO(NR 3 R 4 ), SC(NH 2 )═NR 5 , or when m=1, comprises an oxirane ring with the adjacent oxygen atom; R 3 , R 4 , and R 5 are independently H or alkyl; and X is H, HO, Cl, Br, I, F, or alkoxy.
Claim 4
Dependent Claim
64 words
The substituted anthraquinone of claim 2 wherein R 1 and R 2 independently are lower alkyl; m and n are 1; A is Cl, Br, OCO(NR 3 R 4 ), SC(NH 2 )═NR 5 , or when m=1, comprises an oxirane ring with the adjacent oxygen atom; R 3 , R 4 , and R 5 are H; and X is H or OH.
Claim 5
Dependent Claim
22 words
A pharmaceutical composition for inhibiting protein kinase C comprising a substituted anthraquinone of claim 1 and a pharmaceutically acceptable carrier or diluent.
Claim 6
Dependent Claim
22 words
A pharmaceutical composition for inhibiting protein kinase C comprising a substituted anthraquinone of claim 2 and a pharmaceutically acceptable carrier or diluent.
Claim 7
Dependent Claim
22 words
A pharmaceutical composition for inhibiting protein kinase C comprising a substituted anthraquinone of claim 3 and a pharmaceutically acceptable carrier or diluent.
References Cited (Backward Citations)
US1540733A
Cited
US2411148A
Cited
US3960751A
Cited
US4197249A
Cited
US4310666A
Cited
US4526989A
Cited
US4598155A
Cited
US4540788A
Cited
US4762648A
Cited
US4894451A
Cited
JPS6315853A
Cited
US4816450A
Cited
JPH0219819A
Cited
DE3827974A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-19 | 1996-10-19 | 1997-04-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-19 | 2000-10-19 | 2001-04-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-19 | 2004-10-19 | 2005-04-20 | $7700.00 | Window Closed / Lapsed |